- New management in place with proven track record of bringing several anti cancer drugs to commercial markets.
2) $50 mln deal with GPC Biotech for Satraplatin that is a phase 3 drug
3) Insiders buying heavily
4) Several drugs in pipeline with billions of dollars potential.
5) Float is tiny - under 3 mln shares
6) Market capital is very low - under $4 mln
7) Float mostly in hands of investors in for long term
8) Entry into Generic drugs business which has US market potential of north of $15 bln/yr
9) Attractive buyout candidate
10) Strategic investment & deal with India’s leading Pharmaceuticals company JB Pharma & Chem
11) Company has spend over $150 millions in research over the last 10+ years
kui ta tõuseks kahe nädalaga 7 peale, siis võibolla ostaks
WWTR - praegu on 0.25. kaks aastat järjest on olnud 1,0 aprillis. kas ka seekord. kas ma olen liiga naiivne
võibolla osta täna, lootes homsele põrkele?
SPPI edasine noteerimine NASDAQil on küsimärk.Küllaldane põhjus mitte osta:(
Täna +46%
2) $50 mln deal with GPC Biotech for Satraplatin that is a phase 3 drug
.... osta siis parem juba GPC Biotechi, kellel on võimalus päris mõjukaks ravimifirmaks kujuneda.
.... osta siis parem juba GPC Biotechi, kellel on võimalus päris mõjukaks ravimifirmaks kujuneda.